



# Transforming cancer treatment with Protein Phosphatase 2A inhibitors

Unveiling the first of a novel class of therapeutic agents

**LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company developing a new class of cancer therapy called PP2A inhibitors.**

The Company's innovative approach enhances the efficacy of both chemotherapy and immunotherapy, potentially providing new treatment options for patients. At the core of the Company's therapy is LB-100, the Company's proprietary compound that acts as an inhibitor of PP2A with a favorable toxicity profile. LB-100 promotes the production of cytokines, boosts T-cell proliferation, and generates neoantigens. Moreover, it disrupts the DNA repair mechanisms of cancer cells, potentially improving treatment outcomes. The Company is conducting multiple clinical trials for solid tumors with unmet medical needs. The Company's unique approach has no known competitors and is covered by a comprehensive patent portfolio.

## Pioneering a novel class of cancer therapy

Chemotherapy and immunotherapy face common challenges that have limited their success rates, including limited efficacy due to resistance and potential for side effects that can restrict the dosage or duration of treatment.

LIXTE has pioneered a novel class of cancer therapy that strongly enhances the efficacy of both chemotherapies and immunotherapies in pre-clinical models.

At the core of this approach lies our proprietary compound, LB-100, which acts as an inhibitor of PP2A, a critical enzyme involved in multiple cellular functions.

## LIXTE has developed a first-in-class enhancer of chemotherapy and immunotherapy

### CHEMOTHERAPY

+ LB-100

#### Enhanced chemotherapy efficacy

- Stimulates cell cycle
- Inhibits DNA repair



### IMMUNOTHERAPY

+ LB-100


#### Enhanced immunotherapy efficacy

- Enhances T cell proliferation
- Increases release of cytokines
- Promotes production of neoantigens

## LB-100 is a first-in-class PP2A-inhibitor and has a promising safety profile

LB-100 is a small molecule inhibitor of PP2A, a critical enzyme involved in multiple cellular functions.

- Demonstrated safety in phase 1 clinical trials
- Demonstrated anti-cancer activity in 25+ publications
- Convenient IV delivery and cost-effective manufacturing
- Good Manufacturing Practice production in place
- FDA: Investigational New Drug status
- EMA: Investigational Medicinal Product Dossier approval in Europe in 2022



LB-100


“  
In addition to pursuing novel therapies, we believe we should try to increase the efficacy of existing treatments so that they work for a broader range of patients.”

## LIXTE already has proof of concept that it works: Inhibition of PP2A by LB-100 is effective in numerous cancer models

LB-100 has been shown to inhibit a spectrum of human cancers.

In extensive pre-clinical studies, LB-100, when coupled with standard cytotoxic drug therapies, potentiates the effectiveness of such regimens against hematologic cancers and solid tumors without enhancing toxicity.

In addition, as recently shown, low doses of LB-100 significantly increase the effectiveness of PD-1 immune-checkpoint blockade by activating cytotoxic T cells and CAR-T cells.



Tumors with a PP2A inactivating mutation (red line) have a much better response and thus survival when treated with immunotherapy.  
**Nature 2025 Dai et al**

## LIXTE is building a robust pipeline in multiple cancer indications

LB-100 + Immunotherapy

### Ovarian Clear Cell Cancer

NCT06065462

Phase 1b/2

Status: Recruiting

LB-100 + Immunotherapy

### Metastatic MSS Colon Cancer

NCT06012734

Phase 1b

Status: Recruiting

LB-100 + Chemotherapy

### Advanced Soft Tissue Sarcoma

NCT05809830

Phase 1b/2

Status: Data Analysis 1b

## Led by an experienced and committed team

Our team brings decades of collective expertise in clinical and drug development, ensuring comprehensive knowledge and experience in advancing innovative therapies. Our Scientific Advisory Committee is comprised of esteemed business leaders and renowned key opinion leaders in the fields of clinical medicine and oncology.

### Management

Geordan Pursglove CEO & Chair of the Board An accomplished executive and entrepreneur with 10+ years of experience in M&A, capital markets, strategy, and operations.

Bas van der Baan, CSO & President. Biotechnology Executive with more than 20 years experience in bringing innovation to the patient. Most recently the Chief Clinical Officer of Agendia.

Peter Stazzone, CFO Seasoned CFO with 25 years of expertise in finance operations management and accounting across start-ups, high-growth ventures, and multi-billion-dollar enterprises.

### Scientific Advisory Committee

Prof. René Bernards. Leader in the field of molecular carcinogenesis. Extensive experience in cancer drug development. Netherlands Cancer Institute in Amsterdam

Stephen Forman, MD. Internationally recognized expert in hematological cancers. Professor of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center

Yun Yen MD, PhD, FACP. Distinguished cancer investigator. Former Chairman, Molecular Pharmacology, City of Hope. Former President of Taipei Medical University

## Key Investment Considerations

### Clinical-stage

Pharmaceutical company developing a new class of cancer therapy called PP2A inhibitors.

### Innovative Approach

Enhancing chemo- and immunotherapy efficacy, providing new options for cancer patients.

### Unique Mechanism of Action

Proprietary compound LB-100 acting as a safe and potent inhibitor of PP2A.

### Broad Impact

Conducting multiple clinical trials for solid tumors, including Advanced Soft Tissue Sarcoma, Ovarian Clear Cell Cancer and Colon Cancer.

**LIXTE**<sup>TM</sup>

**www.liخته.com**  
LIXTE Biotechnology Holdings, Inc.  
433 Plaza Real Suite 275 Boca Raton FL 33432

General Phone: +1 631 830-7092 I  
Email: info@liخته.com